Other Health News Topics Other STDs Herpes
Researchers Report Setbacks on Herpes Simplex Vaccine and Treatment
- Details
- Category: Herpes
- Published on Friday, 24 February 2012 00:00
- Written by Liz Highleyman
An experimental herpes simplex virus (HSV) vaccine partially protected women against infection with HSV type 1 but not type 2, according to a recent report in the New England Journal of Medicine. Another recent study found that antiviral treatment with acyclovir (Zovirax) or valacyclovir (Valtrex) did not prevent periodic HSV-2 reactivation and viral shedding.
Tenofovir Microbicide Gel May Prevent Genital Herpes in Addition to HIV Infection
- Details
- Category: Microbicides
- Published on Tuesday, 25 October 2011 00:00
- Written by Press Release
A vaginal gel containing the HIV nucleotide reverse transcriptase inhibitor tenofovir (known as Viread in pill form, also in the Truvada and Atripla coformulations) inhibits replication of herpes simplex virus, researchers reported in the October 4, 2011, issue of Cell Host and Microbes. Tenofovir gel has already been shown to reduce HIV infection by about 40%, and the new findings suggest it may have a dual benefit.
Genital Herpes Virus Can Spread Despite Lack of Symptoms
- Details
- Category: Herpes
- Published on Saturday, 23 April 2011 05:17
- Written by Liz Highleyman
People without genital sores or other symptoms can still shed and transmit herpes simplex virus type 2 (HSV-2) during sex, according to a recent U.S. study. 
IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 02 August 2011 00:00
- Written by Liz Highleyman
Several studies presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last month in Rome showed that treating herpes simplex virus type 2 (HSV-2) with acyclovir or valacyclovir (Valtrex) reduced HIV viral load and slowed disease progression.
Oral Tenofovir Does Not Reduce Herpes Virus Shedding
- Details
- Category: Herpes
- Published on Tuesday, 25 January 2011 12:55
- Written by Liz Highleyman
HIV positive people who took tenofovir (Viread, also in the Truvada and Atripla combination pills) as part of their antiretroviral regimen were no less likely to shed herpes simplex virus 1 or 2 (HSV-1 or HSV-2) than individuals using non-tenofovir regimens, according to research described in the January 14, 2011, issue of AIDS. These findings are notable because a recent microbicide study found that a tenofovir gel reduced the likelihood of HSV-2 infection.
Web Design and Development by